Selecta partners with Juvenile Diabetes Research Foundation (JDRF) to develop Selecta's antigen-specific tolerogenic Synthetic Vaccine Particles (SVP) technology to treat Type I diabetes

Selecta Biosciences Inc.

U.S. / Private Biopharma

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

JDRF

U.S. / Non-Profit or Major Disease Foundation

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Sanofi

France / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced